Research Peptide Naming and Identity Problems

Four layers that get mixed up

Keep these apart whenever you read a claim. See also How to Read a Peptide Record.

1. Molecule: the exact chemical entity, such as a defined sequence or an international nonproprietary name.
2. Formulation: the molecule plus other ingredients, form and any chemical modification.
3. Product or brand: a named item that a company sells.
4. Alias or marketing name: a nickname, code or abbreviation used by sellers or forums.

A published trial tells you about layer 1 and 2 as studied, in one population. It says nothing about a different thing sold under the same alias. Related ideas are in Natural, Synthetic and Modified Peptides.

Worked examples from sources we read

What tests of real products found

These studies measured products, not people. They do not say a particular product is safe or unsafe, only that identity and strength cannot be taken from the label.

• Falsified peptide drugs (Belgium). Ten frequently seen falsified peptide drugs from three suspected illegal internet pharmacies had large variation in amount, purity of 5% to 75% for some peptides, and in some samples arsenic and lead. [12]
• Melanotan II vials. Vials from three online shops held 4.32 to 8.84 mg against a claimed 10 mg, and two shops' vials had unknown impurities. [13]
• Melanotan II nasal sprays. Australian regulator testing estimated 22 to 54 mg per bottle on bottles labelled 30 mg. [14]
• Products sold as SARMs. Of 44 products, 52% contained a SARM, 39% another unapproved drug (including ibutamoren), and only 18 of 44 matched the label amounts. [10]
• Growth hormone sold online. In a study of 17 vendor sites, all samples had significantly lower somatropin than labelled, and none showed a regulator logo. [15]
• European official laboratories. Of 324 suspected illegal products, 65% were presented as medicines and 24% as dietary supplements; some contained doses described as overdoses. [16]

Registry records and "research use only"

Even official-looking records can mislead. A ClinicalTrials.gov record for a "TB-500" trial (NCT07487363) describes itself as a "fictional study" that is "an example", and a melanotan II vitiligo record (NCT07437560) calls itself an "example" record. Both come from the same listed sponsor. [17][18] A registered number does not by itself prove that a real, ethically approved study exists; look at who runs it and whether results or publications follow. Likewise a "research use only" label is a seller's statement, not a safety or quality assurance: see Research Use Only Labels. Regulators treat several of these compounds differently: the FDA's category 2 list says compounded drugs containing some of them may pose risks such as immunogenicity (immune reaction to the drug) and difficulty characterizing the active ingredient. [1]

Why this changes how to read claims

• Match every part. If a claim cites a study, ask whether the exact molecule, form and population match what is sold.
• Biomarker is not benefit. Higher growth hormone or IGF-1 in a trial is not an outcome that matters to patients by itself. [19]
• Absence of reports is not safety. The FDA says it has "no human exposure data" for some listed compounds, such as TB-500; that means unknown, not safe. [1]
• Sport adds another layer. Anti-doping lists name classes and examples such as TB-500 and ibutamoren. [6] See Sports Anti-Doping Rules for Peptides.

What to do instead

Do not use a vial's label, a certificate or a website to decide a product is what it says. Ask a doctor or pharmacist about approved options, and report side effects to your regulator. For more on evaluating marketing, read How to Evaluate Peptide Claims.